BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers

Pharmaceutical

BerGenBio

BerGenBio's headquarters in Bergen, Norway

Gayle Mills

Rune Skeie

Sally Bennet

Anders Tullgren

John Heymach

Debra Barker

Enriqueta Felip

Tony Mok

Solange Peters

The Leadership Team at BerGenBio is responsible for setting strategic direction and overseeing the organization's operations to advance the development of first-in-class AXL inhibitors. Comprising the CEO, CFO, and Chief Business Officers, the team focuses on driving business growth, ensuring financial sustainability, and fostering partnerships to bring innovative treatments for aggressive, treatment-resistant cancers to market. Their leadership is crucial in aligning scientific and commercial objectives to achieve the company's mission.

Leadership Team

The Scientific Team at BerGenBio is responsible for conducting cutting-edge research to develop and optimize first-in-class AXL inhibitors. Comprised of expert Scientific Advisors, the team focuses on understanding disease mechanisms, designing experimental studies, and translating scientific findings into clinical applications to combat advanced, treatment-resistant cancers.

BerGenBio

Org chart

Board & advisors

Teams

Leadership Team

Scientific Team

Offices

BerGenBio

Org chart

Board & advisors

Teams

Leadership Team

Scientific Team

Offices

Related companies